Association of serum uric acid and non-motor symptoms in Parkinson's disease: A cross-sectional study from a movement disorders clinic in Lagos, Nigeria

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL
Olanike Odeniyi, O. Ojo, I. Odeniyi, N. Okubadejo
{"title":"Association of serum uric acid and non-motor symptoms in Parkinson's disease: A cross-sectional study from a movement disorders clinic in Lagos, Nigeria","authors":"Olanike Odeniyi, O. Ojo, I. Odeniyi, N. Okubadejo","doi":"10.4103/jcls.jcls_29_22","DOIUrl":null,"url":null,"abstract":"Background and Objective: The role of serum uric acid (SUA) as a biomarker in Parkinson's disease (PD) remains exploratory and has not been described in our population. The objective of this study was to explore the profile of SUA and its relationship to nonmotor symptoms (NMS) burden in PD. Methods: This cross-sectional study recruited 70 persons with PD and 140 matched healthy controls in Lagos, Nigeria. PD was diagnosed using the United Kingdom PD Society Brain Bank criteria. NMS were assessed with the NMS Questionnaire (NMS-Quest). SUA was measured using standard methods. Results: The mean ages of PD and controls were 63 ± 9.4 years and 62.9 ± 8.8 years, respectively (P = 0.65), with no difference when compared by sex. The median PD duration (interquartile range [IQR]) was 4 (4.25) years. Median Hoehn and Yahr stage (IQR) was 2.5 (1.0). The mean total unified Parkinson's disease rating scale score was 70.7 ± 23.7. The mean NMS-Quest score was 8.5 ± 3.8. Mean SUA level was significantly lower in PD compared to controls (2.42 ± 0.75 mg/dL vs. 3.73 ± 1.09 mg/dL [P = 0.000]). There was a nonsignificant inverse linear trend of association (r = −0.184; P = 0.126) between the total NMS-Quest score and SUA level in PD. Logistic regression analysis revealed hyposmia and memory impairment were significantly related to lower SUA levels (P = 0.02 and P = 0.04, respectively). Conclusion: Our study corroborates the potential of SUA as a serum biomarker in PD and a possible role in defining non-motor symptom burden. Further exploration to clarify the association and interrogate the impact of interventions is warranted.","PeriodicalId":15490,"journal":{"name":"Journal of Clinical Sciences","volume":"23 1","pages":"104 - 109"},"PeriodicalIF":0.2000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcls.jcls_29_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 1

Abstract

Background and Objective: The role of serum uric acid (SUA) as a biomarker in Parkinson's disease (PD) remains exploratory and has not been described in our population. The objective of this study was to explore the profile of SUA and its relationship to nonmotor symptoms (NMS) burden in PD. Methods: This cross-sectional study recruited 70 persons with PD and 140 matched healthy controls in Lagos, Nigeria. PD was diagnosed using the United Kingdom PD Society Brain Bank criteria. NMS were assessed with the NMS Questionnaire (NMS-Quest). SUA was measured using standard methods. Results: The mean ages of PD and controls were 63 ± 9.4 years and 62.9 ± 8.8 years, respectively (P = 0.65), with no difference when compared by sex. The median PD duration (interquartile range [IQR]) was 4 (4.25) years. Median Hoehn and Yahr stage (IQR) was 2.5 (1.0). The mean total unified Parkinson's disease rating scale score was 70.7 ± 23.7. The mean NMS-Quest score was 8.5 ± 3.8. Mean SUA level was significantly lower in PD compared to controls (2.42 ± 0.75 mg/dL vs. 3.73 ± 1.09 mg/dL [P = 0.000]). There was a nonsignificant inverse linear trend of association (r = −0.184; P = 0.126) between the total NMS-Quest score and SUA level in PD. Logistic regression analysis revealed hyposmia and memory impairment were significantly related to lower SUA levels (P = 0.02 and P = 0.04, respectively). Conclusion: Our study corroborates the potential of SUA as a serum biomarker in PD and a possible role in defining non-motor symptom burden. Further exploration to clarify the association and interrogate the impact of interventions is warranted.
血清尿酸与帕金森病非运动症状的关系:尼日利亚拉各斯一家运动障碍诊所的横断面研究
背景与目的:血清尿酸(SUA)作为帕金森病(PD)的生物标志物的作用仍处于探索性阶段,尚未在我们的人群中进行描述。本研究的目的是探讨SUA的概况及其与PD患者非运动症状(NMS)负担的关系。方法:本横断面研究在尼日利亚拉各斯招募了70名PD患者和140名匹配的健康对照。PD的诊断采用英国PD协会脑库标准。采用NMS问卷(NMS- quest)对NMS进行评估。采用标准方法测定SUA。结果:PD组和对照组的平均年龄分别为63±9.4岁和62.9±8.8岁(P = 0.65),性别差异无统计学意义。PD持续时间中位数(四分位间距[IQR])为4(4.25)年。Hoehn和Yahr分期(IQR)中位数为2.5(1.0)。帕金森病统一评定量表平均总分为70.7±23.7分。NMS-Quest平均评分为8.5±3.8。PD患者的平均SUA水平明显低于对照组(2.42±0.75 mg/dL vs. 3.73±1.09 mg/dL [P = 0.000])。存在不显著的线性反相关趋势(r = - 0.184;P = 0.126) NMS-Quest总分与PD患者SUA水平之间的差异。Logistic回归分析显示,低SUA水平与睡眠不足和记忆障碍显著相关(P = 0.02和P = 0.04)。结论:我们的研究证实了SUA作为帕金森病血清生物标志物的潜力,并可能在确定非运动症状负担方面发挥作用。进一步的探索,以澄清关联和询问干预措施的影响是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Sciences
Journal of Clinical Sciences MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
15
审稿时长
45 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信